Spectrum

Psychiatry › Articles

The World Wonky After the Trip: Understanding Visual Distortions from HPPD

Medically Reviewed by Dr. Narayanan Mooss and Ms Muktha Updated on June 03, 2026

Contributors

Dr. Narayanan Mooss

Ayurvedic Psychiatrist

Ms. Muktha

Clinical Psychologist

Key Take Aways

Hallucinogen Persisting Perception Disorder (HPPD) is a rare but recognised condition in which visual disturbances continue after hallucinogen use has stopped, while the person still understands that these perceptions are not real unlike psychosis. Symptoms can include visual snow, afterimages, tracers, light sensitivity, altered visual perception, and derealisation, often accompanied by anxiety and stress. Current evidence suggests HPPD involves dysregulation in the brain’s visual processing and inhibitory systems, which is why treatments such as lamotrigine, clonazepam, CBT, stress reduction, good sleep hygiene, and complete avoidance of psychoactive substances especially cannabis can significantly improve recovery outcomes. Ayurveda and yoga view HPPD through severe Vata imbalance and nervous system dysregulation, supporting stability through grounding routines, calming herbs like Ashwagandha and Brahmi, pranayama, Abhyanga, mindfulness, and restorative yoga practices. With appropriate medical support, symptom management, and sustained nervous system regulation, significant improvement and even full recovery are realistic for many individuals.

Full Article

When the afterglow never fades: Navigating the persistent visual world of Hallucinogen Persisting Perception Disorder.

For instance, you might wonder:

All of these questions are normal and it’s understandable that you want to support your loved one to the best of your ability

While your questions are valid, it’s also important to understand that every person’s experience with depression is unique, so there are a few things you can do to help your loved one and yourself.

What Is HPPD? Unpacking the Unwanted Encore

Imagine coming off a psychedelic trip days, weeks, or even months ago -and noticing that something in your visual world hasn’t quite returned to normal. There’s static at the edges of things. Objects leave trails as they move. When you stare at a blank wall, it seems to breathe or pulse. The trip is technically over, but your visual system hasn’t fully filed the experience away.

This is the territory of Hallucinogen Persisting Perception Disorder -HPPD. It is a rare but real condition in which a person continues to experience perceptual disturbances, primarily visual, after hallucinogenic drug use has stopped. These are not brief nostalgic flashbacks. They are ongoing -present in the sober, non-intoxicated state -and for many people, they are distressing and disruptive to daily life.

HPPD is formally recognised in the DSM-5 (diagnostic code 292.89, F16.983) and in the ICD-10 (F16.7). The DSM-5 defines it as the recurrence of one or more of the perceptual symptoms that were experienced during hallucinogen intoxication, following cessation of use, causing clinically significant distress or impairment in functioning, and not better explained by another medical or psychiatric condition. A critical feature: reality testing remains intact. People with HPPD know their visual disturbances are caused by the drug’s lingering effects -they are not psychotic, and they are not hallucinating in the full clinical sense of the word. They are perceiving. The perception is just wrong.

HPPD is classified under two informal subtypes that, while not yet officially codified in the DSM-5, are well-recognised clinically. Type 1 (sometimes called HPPD I) involves brief, intermittent flashbacks -isolated episodes of re-experiencing perceptual distortions from intoxication. These tend to be mild, transient, and experienced by some as not particularly distressing (some users even describe them as ‘free trips’). Type 2 (HPPD II) is the more serious presentation: persistent, chronic, waxing-and-waning perceptual disturbances that may persist for months to years, accompanied by significant anxiety, distress, and functional impairment. This is the type that drives people to seek clinical help.

The exact prevalence of HPPD is genuinely unknown. It is considered rare in clinical settings, but surveys of psychedelic users have suggested that up to 60% report some degree of HPPD-like visual phenomena -though only 4.2% in one survey considered their symptoms severe enough to seek treatment. Up to 50% of clinical cases may resolve spontaneously over time. HPPD is not contagious, not a sign of underlying psychosis, and not a guarantee of permanent visual change.

An important distinction: HPPD is not the same as psychosis. The defining clinical feature is intact reality testing -the person knows the disturbances are a perceptual artefact, not a genuine reflection of the external world. This is fundamentally different from hallucinations in schizophrenia or drug-induced psychosis, where the person cannot distinguish perception from reality. This distinction matters for treatment: antipsychotics, which are the first-line treatment for psychosis, have frequently been found to be unhelpful or even symptom-worsening in HPPD.

"The only way out of the labyrinth of suffering is to forgive."

Decoding the Distortions: HPPD Symptoms Explained

HPPD symptoms are predominantly visual –a reflection of the mechanism of the condition, which appears to involve dysregulation of the visual processing system. The range of symptoms is broader than many people realise, and not everyone experiences the same set. A 2022 case series of 13 patients found that the most frequent presentations were visual snow, floaters, palinopsia (persistent afterimages), photophobia (light sensitivity), and nyctalopia (difficulty seeing in low light). Researchers have noted that the DSM-5’s formal symptom list doesn’t fully capture the range of what HPPD patients actually experience, including visual snow, photophobia, and floaters that are common in clinical presentations but absent from the official criteria.

Here is what the main symptoms actually look, feel, and function like for the people living with them:

Visual snow: A continuous flickering or static overlay on the visual field -like trying to watch the world through an old, poorly-tuned television. Unlike the floaters most people occasionally notice, visual snow in HPPD is persistent, covers the whole field, and doesn't resolve in different lighting conditions. It can make text difficult to read and faces harder to process.
Trails and tracers (palinopsia): Objects leave a ghost image or smear behind them as they move -a car driving past leaves a trail; a hand waving persists in a sweep of after-images. This is formally called palinopsia and can be particularly disorienting during driving or in busy visual environments.
Afterimages: Seeing a residual visual impression of something after you've looked away -an afterimage of the light fixture persists when you look at the wall; the shape of a window lingers in the opposite wall. In daily life, this can make it difficult to visually 'clear' previous inputs before processing new ones.
Intensified or enhanced colours: Colours appear supersaturated and unnaturally vivid -beautiful in description, but often overwhelming and disorienting in practice, particularly in brightly lit or colourful environments.
Distorted size perception and apparent motion: Objects appear smaller than they are (micropsia) or larger (macropsia). Surfaces or flat patterns may seem to move, shimmer, or breathe. Peripheral visual movement that doesn't correspond to actual motion can trigger startle responses and ongoing vigilance.
Light sensitivity (photophobia) and difficulty in low light: Bright lights, sunlight, and screens produce more discomfort than they used to. Many HPPD sufferers develop strategies to manage their environment -sunglasses indoors, screen brightness reduced to minimum, avoidance of flashing lights. This sensitivity is often worsened by stress and poor sleep.
Derealisation and depersonalisation: A sense of unreality or disconnection from one's surroundings (derealisation) and/or a sense of being detached from one's own mind and body (depersonalisation). These are not visual symptoms, but they frequently accompany HPPD, particularly in Type 2 presentations, and significantly compound the distress.

The distress generated by HPPD symptoms is not simply about the visual disruption itself. It is frequently about the anxiety that accompanies it –the catastrophic worry about permanence, the hypervigilant self-monitoring of every visual oddity, the fear that the symptoms signal something more serious. This anxiety-HPPD feedback loop is clinically important: stress worsens visual symptoms; worsening visual symptoms increase anxiety; and so the cycle accelerates. Panic disorder, alcohol use disorder, and major depressive disorder are all documented comorbid conditions in HPPD.

Why Me? Risk Factors and Root Causes

Why does HPPD develop in some people who use hallucinogens and not others? The honest answer is that we don’t fully know –HPPD remains one of the more poorly understood conditions in psychiatry, partly because it is rare enough that large-scale studies are difficult to conduct, and partly because its neurobiological mechanisms are still being worked out. What is known points toward a condition of individual vulnerability rather than simple dose-response toxicity.

Neurobiological hypotheses

The leading neurobiological theory is that HPPD results from chronic disinhibition of visual processors following hallucinogen use. Under normal circumstances, the visual system has inhibitory interneurons that regulate and filter perceptual input –keeping the baseline level of visual noise low. Classic hallucinogens like LSD act as potent agonists at 5-HT2A serotonergic receptors, which are concentrated in these inhibitory interneurons. The hypothesis is that, in susceptible individuals, hallucinogen exposure leads to excitotoxic damage or long-term dysregulation of these GABAergic inhibitory interneurons, removing the ‘brake’ from visual processing. The result is chronic disinhibition: too much visual signal coming through, not enough filtering –the equivalent of turning off the noise-cancelling function of the visual system.

This hypothesis is supported by the relative effectiveness of anticonvulsants (particularly lamotrigine) in managing HPPD symptoms –drugs that work by stabilising neuronal excitability and reducing excessive neuronal firing. It also explains why SSRIs are often counterproductive in HPPD: by increasing serotonergic activity at 5-HT2A receptors, they can paradoxically worsen the very dysregulation that underlies the condition. A 2024 scientific reports study of neuropsychological profiles in HPPD patients found distinct cognitive patterns compared to psychedelic-using controls, suggesting that HPPD involves measurable neuropsychological changes beyond the purely visual.

Risk factors

Several factors appear to increase the likelihood of developing HPPD, though none are deterministic –the condition has appeared after even a single exposure in individuals with no apparent risk factors:

Type of substance: LSD has historically been most commonly associated with HPPD, but this may partly reflect its historically greater popularity as a psychedelic rather than an intrinsic quality of LSD specifically. A 2022 clinical review found no significant difference in the induction of subclinical visual phenomena between MDMA, LSD, and psilocybin. Cannabis and other cannabinoids, MDMA, ketamine, and even benzodiazepine withdrawal have all been associated with HPPD presentations. There does not appear to be a dose-response correlation -having a single use can produce HPPD in susceptible individuals, and frequent heavy use does not necessarily produce it.
Frequency of use: More frequent hallucinogen use does appear to increase overall risk, though the absence of a dose-response relationship means this is probabilistic rather than predictive.
Pre-existing mental health conditions and individual vulnerability: Anxiety disorders, depression, a prior history of psychosis, and pre-existing visual phenomena (tinnitus, floaters, difficulty concentrating) are all associated with higher HPPD vulnerability. This suggests that people with already-sensitised nervous systems or lower baseline inhibitory regulation are at greater risk.
Genetic predisposition: The idiosyncratic pattern of HPPD -appearing in some and not others despite similar usage histories -strongly suggests genetic predisposition. Family histories of anxiety disorders and specific pre-drug visual or perceptual sensitivities may predict vulnerability. The condition may also be more likely when drugs acting on 5-HT2A receptors are combined with SSRIs, due to drug-drug interactions at those receptors.
Set and setting at time of use: Using hallucinogens in settings of high stress, poor sleep, or psychological instability may increase risk. Set and setting -the psychological context of drug use -matters not just for the immediate experience but potentially for whether the perceptual system can return to baseline afterward.

The Western Approach: Diagnosis and Management

Getting an HPPD diagnosis can be frustratingly difficult –not because the condition is obscure to those who know it, but because many clinicians have limited familiarity with it. Patients frequently describe being misdiagnosed with anxiety disorder, panic disorder, schizophrenia, or psychotic depression before finding a psychiatrist or neurologist who recognises the specific cluster of persistent post-hallucinogen visual phenomena. The importance of finding a clinician with HPPD experience cannot be overstated: as the research literature confirms, antipsychotics are often not merely unhelpful for HPPD but can actively worsen symptoms –so a misdiagnosis of psychosis and incorrect treatment can cause real harm.

Diagnosis

A formal HPPD diagnosis requires ruling out other potential causes of visual disturbances: brain lesions, infections, epilepsy (particularly visual epilepsy), migraine with aura, ophthalmological conditions (optic neuritis, retinal disorders), and psychiatric conditions (psychosis, severe anxiety). This means a thorough evaluation including medical and psychiatric history, a neurological examination, ophthalmological assessment, and typically neuroimaging –though brain imaging is usually normal in HPPD, it is important to rule out structural or vascular causes. Electroencephalography (EEG) may be obtained to exclude seizure-related visual phenomena. The diagnosis, after all of this, is a clinical one: the characteristic symptom pattern, the known hallucinogen exposure history, intact reality testing, and the absence of alternative explanations.

A key diagnostic feature noted by the 2022 case series (Frontiers in Neurology) is that there are typically no significant findings on ophthalmic examination –the eyes are structurally normal. The problem is in the visual processing system, not the optical apparatus. This is important both clinically (it means that standard optometry won’t resolve HPPD) and for the patient’s understanding of their own condition.

Management: Medication

There are no specifically approved medications for HPPD, and all pharmacological approaches are based on case reports, small case series, and limited open-label trials. A 2024–2025 systematic review (PMC/Harvard Review of Psychiatry) analysed 31 studies with 87 participants treated with various medications. Key findings:

Lamotrigine (anticonvulsant): The anticonvulsant lamotrigine (typically used for epilepsy and bipolar disorder) is currently the most widely used medication for HPPD. In a landmark case, a 33-year-old with 18 years of HPPD had near-complete resolution of complex visual disturbances after 12 months on lamotrigine. In the 2024-25 systematic review, lamotrigine was used in 9 participants and produced partial improvement. Its mechanism -reducing glutamate-mediated excitatory transmission and stabilising neuronal firing -directly addresses the disinhibition hypothesis of HPPD. SSRIs should be used cautiously in HPPD; they have been reported to worsen derealisation and depersonalisation in some patients.
Clonazepam (benzodiazepine): Clonazepam (a benzodiazepine) is among the more consistently reported effective treatments in HPPD. A 2003 open-label study of 16 LSD-related HPPD patients treated with 2 mg daily clonazepam found significant improvement on all outcome scales at two months and sustained benefit at six-month follow-up. Clonazepam works by enhancing GABAergic inhibitory activity -directly compensating for the loss of inhibition thought to underlie HPPD. Long-term benzodiazepine use carries risks of dependence and tolerance, and this must be weighed carefully in clinical decision-making.
Clonidine and levetiracetam: Clonidine (an alpha-2 adrenergic agonist) is sometimes used as first-line alongside benzodiazepines, particularly for HPPD presentations with prominent sympathetic arousal. A pilot study of 8 patients reported significant symptom reduction. Levetiracetam (an anticonvulsant) has shown substantial symptom reduction in at least one observational study.

Across the 87 treated participants in the 2024-25 systematic review, 28% achieved full recovery and 61% achieved partial recovery within a year of pharmacological treatment –encouraging figures, though they reflect a heterogeneous group with different medications and presentations. Antipsychotics (risperidone, haloperidol) should generally be avoided –classical antipsychotics are not helpful and may worsen symptoms; atypical antipsychotics have produced mixed results and some reports of paradoxical worsening.

Management: Non-Pharmacological Approaches

Psychotherapy, particularly CBT and anxiety-focused approaches, plays an important role in HPPD management –primarily because the anxiety and distress that HPPD generates are often as debilitating as the visual symptoms themselves, and because the anxiety-symptom feedback loop actively maintains and worsens the condition. Case reports of psychotherapy for HPPD consistently describe benefit from anxiety reduction, muscle relaxation, destigmatisation of visual phenomena, and cognitive reframing of symptoms as non-threatening. The strategy of acceptance and normalisation –learning to acknowledge the visual disturbances without catastrophising about them –reduces the fear response that amplifies symptoms. Eye movement desensitisation and reprocessing (EMDR) has also been reported as potentially helpful in some cases.

A 2024 case report published in Brain Stimulation documented the first successful use of repetitive transcranial magnetic stimulation (rTMS) targeting the right temporoparietal junction in a treatment-resistant Type 2 HPPD patient who had not responded to clonazepam, lamotrigine, CBT, or escitalopram. Following five days of rTMS treatment (and maintenance sessions every four to six months), the patient achieved full remission of HPPD symptoms over a two-year period. While a single case, this suggests that neuromodulation may be a future therapeutic avenue for refractory HPPD.

Lifestyle factors are critically important and often underemphasised in clinical discussions of HPPD:

Substance abstinence: Complete cessation of all hallucinogens, cannabis, and other psychoactive substances is the single most important step. There is evidence that continued cannabis use, in particular, can maintain or worsen HPPD -and cannabis was a contributing factor in several case series. Alcohol use should also be significantly reduced or eliminated during the active phase of HPPD management.
Stress management: Stress is consistently documented as a trigger for HPPD symptom exacerbation. Active stress management through whichever evidence-based methods work for the individual -CBT, exercise, mindfulness, social connection -directly reduces the symptom burden.
Sleep hygiene: Sleep deprivation worsens HPPD symptoms. Good sleep hygiene -consistent sleep and wake times, reduced screen exposure before bed, dark and quiet sleeping environment -is not optional but clinically relevant.
Environmental modifications: Bright lights, screens, fast-motion videos, and fluorescent lighting can all accentuate HPPD visual symptoms. Wearing sunglasses outdoors, reducing screen brightness, using warm-toned lighting indoors, and limiting exposure to visually intense environments are practical accommodations that reduce daily symptom burden.

Eastern Wisdom: Ayurvedic and Yogic Paths to Balance

HPPD has no Ayurvedic diagnostic equivalent –it is a specific, contemporary clinical presentation that Ayurvedic texts did not encounter. But the underlying phenomenology –a nervous system destabilised by psychoactive substances, producing persistent perceptual disturbance, anxiety, and dysregulated sensory processing –maps onto the Ayurvedic framework with striking clarity. And Ayurveda’s interventions for nervous system dysregulation, anxiety, and perceptual hypersensitivity offer genuinely useful complementary support alongside Western management.

The Ayurvedic Lens: Vata, Prana, and Sensory Channels

In Ayurveda, HPPD-type presentations would be understood primarily as a severe aggravation of Vata dosha –the constitutional principle governing the nervous system, movement, communication, and sensory processing. Vata governs what Ayurveda calls the Manovaha Srotas (the channels of the mind) and, more specifically, Prana Vata –the sub-dosha responsible for the brain, heart, and sense organs. When Prana Vata is disturbed, the result is exactly the cluster that characterises HPPD: erratic sensory processing, heightened sensitivity, anxiety, perceptual instability, difficulty concentrating, insomnia, and a sense of disconnection from reality.

Psychoactive substances, in Ayurvedic understanding, are understood to create powerful but artificial stimulation that distorts Prana Vata and creates Ama (metabolic toxins) that accumulate in the subtle sensory channels (Srotas). The nose is considered the gateway to the brain in Ayurveda –and it is precisely the visual/perceptual system (linked to the head’s channels) that HPPD disrupts. Ayurvedic treatment for this kind of presentation focuses on: clearing accumulated toxins from the sensory channels, grounding and stabilising the aggravated Vata, nourishing and rebuilding the depleted Ojas (the vital essence of resilience and immunity), and restoring the natural regulatory function of the nervous system.

Ayurvedic Dietary Approach

A Vata-pacifying diet creates the internal conditions for nervous system stability. The principle is warmth, oiliness, and regularity –the opposite of the cold, dry, scattered qualities of excessive Vata. Specific recommendations:

Warm, nourishing, grounding foods: Warm soups, stews, kitchari (rice and mung dal), cooked root vegetables, and nourishing grains. Foods that are easy to digest and grounding. Warm ghee as a cooking medium and digestive support. Regular mealtimes at consistent hours -Vata thrives on predictability and is destabilised by irregular eating.
Avoid: Caffeine (already a known HPPD symptom trigger), cold and raw foods, dry snack foods, stimulants, alcohol, and recreational drugs -all of which aggravate Vata and Prana Vata specifically.
Warm drinks: Warm herbal teas -chamomile, holy basil (Tulsi), ashwagandha milk -are both nourishing and calming. Ghee with warm milk before bed is a traditional Ayurvedic sleep and nervous system support.

Medhya Rasayana: Herbs for the Mind and Nervous System

Ayurveda’s Medhya Rasayana herbs –nootropic and neuroprotective formulations specifically indicated for mind-channel (Manovaha Srotas) support –are the most clinically relevant herbal tier for HPPD:

Ashwagandha (Withania somnifera): A powerful adaptogen and Vata-pacifier, Ashwagandha nourishes and strengthens the nervous system, reduces cortisol and stress-system hyperreactivity, and builds resilience against the hypersensitivity that HPPD involves. A 2024 systematic review and meta-analysis of 9 RCTs (558 participants) found significant reductions in perceived stress, Hamilton Anxiety Scale scores, and serum cortisol. It is a mainstay of Ayurvedic protocols for neurological and psychological recovery.
Brahmi (Bacopa monnieri): Brahmi is Ayurveda's premier cognitive and nervous system herb. It calms the mind, supports memory and concentration, reduces anxiety, and has documented neuroprotective properties. It is particularly relevant to HPPD's cognitive and derealisation components. A PMC 2023 systematic review confirmed the efficacy of Brahmi as adjuvant therapy in conditions involving cognitive and anxiety symptoms.
Jatamansi (Nardostachys jatamansi): A nerve relaxant with documented anxiolytic and sleep-supporting properties, Jatamansi is specifically indicated in Ayurveda for conditions involving nervous system dysregulation and perceptual disturbance. It calms Vata and is particularly valued for its grounding effects on the mind.
Shankhapushpi (Convolvulus pluricaulis): Shankhapushpi enhances memory, concentration, and alleviates stress -it is prescribed in Ayurveda for mental fatigue and conditions involving difficulty concentrating, both of which accompany HPPD.

All Ayurvedic herbal interventions should be discussed with a qualified Ayurvedic practitioner before starting, to ensure appropriate formulation, dosage, and combination for your individual constitution.

Panchakarma Therapies

Panchakarma –Ayurveda’s purification and rejuvenation protocols –can support recovery from HPPD’s nervous system dysregulation at the physical level:

Abhyanga (warm oil self-massage): Abhyanga with warm sesame or herbal oil is the most accessible Panchakarma practice for daily home use. Warm oil massage activates the parasympathetic nervous system through skin touch receptors, reduces Vata, and builds the grounded, stable nervous-system baseline that HPPD erodes. A daily 15-minute Abhyanga before showering is both practical and substantively therapeutic.
Shirodhara: A continuous, warm stream of medicated oil poured gently over the forehead and scalp. Shirodhara is specifically indicated in Ayurveda for conditions of the head and nervous system -it produces a measurable shift to parasympathetic dominance and has documented calming effects on brain activity. It is best received through an Ayurvedic clinic.
Nasya (nasal oil therapy): Warm medicated oil administered through the nasal passages -the nose being considered Ayurveda's direct gateway to the brain and Manovaha Srotas. Nasya clears the sensory channels and supports mental clarity. It should be performed under practitioner guidance initially.

Yoga and Pranayama: Grounding the Destabilised System

Yoga for HPPD management prioritises grounding, nervous system regulation, and reduced sensory overwhelm. Vigorous or visually intense practices can be counterproductive during active symptom periods. The emphasis is on:

Grounding and restorative poses: Tadasana (Mountain Pose), Virabhadrasana I (Warrior I), Balasana (Child's Pose), and Savasana (Corpse Pose) build a physical sense of stability and present-moment bodily awareness that counteracts the dissociative, unmoored quality of HPPD. Restorative yoga -supported poses held for 5–10 minutes with blankets and bolsters -activates the parasympathetic system and reduces the sympathetic hyperactivation that worsens symptoms.
Pranayama for parasympathetic activation: Nadi Shodhana (alternate nostril breathing) is particularly relevant to HPPD: it directly regulates the autonomic nervous system, reduces anxiety, and by Ayurvedic theory, balances Prana Vata specifically. Bhramari (humming bee breath) activates the vagus nerve through vibratory resonance, producing rapid calming of the stress system. These are interventions for acute symptom moments as much as daily practices.
Mindfulness practice: For HPPD, mindfulness is practised not to analyse or resolve the visual disturbances, but to develop a different relationship to them: observing them as sensory events rather than threats; noting their presence without fusing with them or catastrophising; recognising that the anxiety about the symptoms is often more disabling than the symptoms themselves. Reduced reactivity to the disturbances reduces the anxiety-HPPD feedback loop that maintains the condition.

A note on Trataka (candle gazing), which is sometimes listed in HPPD-adjacent resources: intense visual concentration practices should be approached with significant caution in active HPPD, as they may increase visual sensitivity and exacerbate symptoms. If pursued, this should only be under the direct guidance of an experienced yoga teacher familiar with HPPD.

Story: Rohan's Uninvited Guests

Rohan was twenty-two when he first used LSD, at a music festival in the third year of his engineering degree. The experience was intense but broadly positive –he described it later as one of the most vivid nights of his life. He used it twice more over the following six months, in controlled settings, and had what he considered meaningful experiences. He wasn’t someone who used drugs carelessly or frequently. He had no significant mental health history.

The change started about a month after the third use. He noticed what he initially described as ‘a kind of visual static’ –particularly visible when he looked at light-coloured walls or the sky. He thought it was eye strain. He went for an eye test; the optometrist found nothing wrong. Over the following weeks, the visual snow became more persistent, and he started noticing trails on moving objects –a fan blade, a hand gesture, a passing car. Objects occasionally seemed to pulse or breathe when he stared at them. Bright lights left halos that persisted longer than they should.

He Googled his symptoms and found HPPD forums. The recognition was immediate and deeply disquieting –he had exactly what was being described, and the forum posts he found ranged from ‘it went away in a few months’ to ‘it’s been three years and I still have it.’ The uncertainty was almost worse than the symptoms. He began monitoring his vision obsessively –which made everything worse. The anxiety about the symptoms began to rival the symptoms themselves. He started avoiding social situations because the visual noise in busy, bright environments became overwhelming. He had his first panic attack in a shopping centre.

His GP referred him to a psychiatrist after his third visit describing visual disturbances that weren’t resolving. The psychiatrist, fortunately, was familiar with HPPD. She explained the condition clearly, reassured him that he was not psychotic, and outlined both the treatment options and the genuine possibility of significant improvement or resolution.

The most important immediate change was cognitive: understanding that his anxiety about the symptoms was actively worsening them. CBT helped him work through the catastrophic thinking –the ‘this is permanent, my brain is damaged, I’ve ruined my life’ narrative –and replace it with a more accurate appraisal: this is a nervous system dysregulation after drug use, it is well-documented, it responds to treatment, and many people recover significantly. He began practising urge-surfing when the anxiety about his visuals surged: observing the anxiety without acting on it, letting it rise and fall. This alone produced noticeable improvement.

His psychiatrist prescribed a low dose of lamotrigine after discussion of the evidence base. Over six months, the visual trails diminished substantially. The visual snow persisted but became less intrusive –partly because he was no longer constantly monitoring it. He added Abhyanga as a daily morning practice on the recommendation of an Ayurvedic practitioner, and found it produced a measurable improvement in his baseline calm. Ashwagandha (a clinically sourced extract, not a generic supplement) helped with the anxiety and sleep disruption. Nadi Shodhana pranayama became his go-to tool when symptoms spiked under stress.

Two years on, Rohan still has some residual visual snow –at its mildest, he barely notices it. He has not used any psychoactive substances since the symptoms started. He graduated, works in software, and has told a handful of close friends about his experience –partly to demystify HPPD for them, and partly because the secrecy and shame had been its own burden. He now participates in an online HPPD support community, occasionally answering questions from recently diagnosed people with the measured perspective of someone who has come through the worst of it.

FAQs:

Q: Is HPPD permanent?

Ans. Not necessarily -and a definitive answer depends on which type is present. HPPD Type 1 (intermittent flashbacks) tends to resolve much more readily than Type 2 (chronic, persistent disturbances). Up to 50% of HPPD cases may resolve spontaneously over time. Among the 87 pharmacologically treated participants in a 2024-25 systematic review, 28% achieved full recovery and 61% achieved partial recovery within a year. With appropriate treatment (lamotrigine, clonazepam, CBT, substance abstinence, stress management), substantial improvement is achievable for most people. The pattern that maintains HPPD -continued substance use, ongoing anxiety, poor sleep, high stress -is also a pattern that responds to intervention. There is genuine reason for optimism, alongside realistic acknowledgment that some people do have lingering symptoms long-term.

Q: Can HPPD develop from cannabis use?

Ans. Yes, and this is more common than the original ‘LSD = HPPD’ narrative suggests. Cannabis has been reported in multiple case series as both a primary trigger and a maintaining/worsening factor for HPPD. In the 2022 case series (Frontiers in Neurology), cannabinoid use was common among HPPD patients, mostly in association with classical hallucinogens. A 2022 clinical review found no significant difference in the induction of subclinical visual phenomena between MDMA, LSD, and psilocybin –suggesting the cannabis-specific risk may be related to how it interacts with a system already sensitised by other psychedelics. Regardless of the original trigger, cannabis use during HPPD recovery is consistently contraindicated –it has been reported to maintain and worsen symptoms.

Q: Is there a cure for HPPD?

Ans. There is no officially approved cure or specific pharmacological treatment. However, ‘no approved cure’ is different from ‘no way to improve’ –and the evidence supports that substantial improvement is achievable for most people with HPPD. The combination of appropriate medication (lamotrigine or clonazepam, chosen by a clinician familiar with HPPD), CBT to address the anxiety feedback loop, complete substance abstinence, and effective stress management produces meaningful improvement in the majority of treated patients. Complete symptom resolution is achievable in a significant proportion, particularly for Type 1 HPPD. The key is finding a clinician who knows what HPPD is and can manage it appropriately –avoiding incorrect treatment (antipsychotics, SSRIs) is as important as finding the right treatment.

Q: What should I do if I think I have HPPD?

Ans. Step one: document your symptoms, their timing (when they started relative to drug use), what makes them worse or better, and their impact on daily functioning. This record will be important for any clinical evaluation. Step two: seek assessment from a psychiatrist or neurologist experienced with HPPD. Not all clinicians are familiar with the condition; it is reasonable to ask specifically whether the practitioner has experience with HPPD before booking. Step three: stop all psychoactive substances immediately, including cannabis and alcohol –this is the single most important lifestyle change and is non-negotiable for meaningful recovery. The HPPD Online community (hppdonline.com) and the r/HPPD subreddit are valuable peer support resources for finding clinician recommendations and shared experience. For a clinical referral, Psychology Today’s therapist finder allows filtering by substance use and related specialisms.

Q: Can anxiety alone cause HPPD-like symptoms?

Ans. This is an important clinical question. Severe anxiety can produce visual anomalies –heightened awareness of normally imperceptible floaters, increased sensitivity to visual phenomena, and derealisation. The relationship between HPPD and anxiety is complex and bidirectional: pre-existing anxiety predisposes to HPPD; HPPD generates anxiety; and anxiety amplifies HPPD symptoms. However, HPPD-specific symptoms –particularly visual snow, palinopsia, afterimages, and trails –are not produced by anxiety alone without prior hallucinogen use. A detailed history of drug use and symptom onset is essential for proper differential diagnosis. In some cases, effective anxiety treatment alone significantly reduces what appeared to be HPPD symptoms, because the hypervigilant self-monitoring of normal visual phenomena was amplified by anxiety to a clinically significant degree.

Conclusion

Living with HPPD can be genuinely hard. The symptoms are isolating –most people have not heard of the condition, and explaining ‘I have persistent visual static and trailing effects from drug use eighteen months ago’ tends to produce either disbelief or unintentionally unhelpful responses. The uncertainty about prognosis compounds the difficulty. And the anxiety that HPPD generates –particularly the catastrophic rumination about permanence and brain damage –can be as disabling as the visual symptoms themselves.

But HPPD is not a permanent sentence. The nervous system that has been dysregulated is also capable of recovery –in many cases substantial recovery, and in a significant proportion, full resolution. The key is accurate diagnosis, appropriate treatment (and the avoidance of inappropriate treatment), complete substance abstinence, effective anxiety management, and the combination of Western clinical tools with whole-system support for the nervous system that Eastern traditions offer.

Understanding what HPPD is, and what it is not, is itself therapeutic. It is not psychosis. It is not permanent brain damage. It is not a sign of inherent weakness or neurological fragility. It is a condition of sensory dysregulation, in specific individuals, following specific exposures –and it responds to treatment.

If you are struggling with HPPD symptoms, please seek professional help from a psychiatrist or neurologist familiar with the condition. HPPD Online (hppdonline.com) and the r/HPPD community can help with clinician recommendations and peer support. The Columbia University Center for Prolonged Grief is not directly relevant –but for any co-occurring severe depression or anxiety, please speak with your GP and remember that crisis support is available: 988 in the US (call or text); Samaritans at 116 123 in the UK.

Relationships

Navigating Life

About Us